Patents Assigned to Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
  • Patent number: 10076541
    Abstract: Compositions comprising L-carnitine or a salt thereof, acetyl L-carnitine or a salt thereof, vitamin B9 (folic Acid), vitamin A, vitamin B12, vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), arginine, vitamin C, vitamin E (?-Tocopherol), selenium, zinc, copper, iron, vitamin D and N-acetyl cysteine, and optionally one or more pharmaceutically acceptable excipients are provided. Dietary supplements comprising these compositions are also provided.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 18, 2018
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Ashraf Virmani, Safouane Zerelli
  • Patent number: 9868757
    Abstract: Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 16, 2018
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Patrizia Ferrari, Giuseppe Bianchi, Mara Ferrandi
  • Publication number: 20170119720
    Abstract: The present invention relates to homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration, in which the resveratrol is solubilized in a solvent system consisting of omega-3 polyunsaturated fatty acids (n-3 PUFA), or their alkyl esters, and a ionic emulsifier. The composition according to the present invention can be formulated as food or nutritional supplement or medicament in the prevention or treatment of cardiovascular diseases due to lipid metabolism disorders and increased platelets aggregation, as well as damages due to free radicals and/or viral diseases.
    Type: Application
    Filed: March 26, 2015
    Publication date: May 4, 2017
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Giuseppe GIANNINI, Mosè SANTANIELLO
  • Publication number: 20160303164
    Abstract: Here is described a synergystic composition for promoting female fertility, comprising as active ingredients L-carnitine, acetyl L-carnitine; N-acetyl cysteine, and several specific vitamins, aminoacids, antioxidants and micro elements.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 20, 2016
    Applicant: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Ashraf VIRMANI, Safouane ZERELLI
  • Patent number: 9457037
    Abstract: A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: October 4, 2016
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Mohamed Ashraf Virmani, Aleardo Koverech
  • Patent number: 9206133
    Abstract: The present invention provides a new process of synthesis of a polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline of Formula I. Said quinoline compound is substantially pure of any impurities. The present invention further provides the use of the above-mentioned polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline in the synthesis of piperaquine or one of its pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: December 8, 2015
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Walter Cabri, Roberto Castagnani, Silvia Armaroli, Gianandrea Quattrociocchi, Vincenzo Colangeli
  • Patent number: 9133197
    Abstract: The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: September 15, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Walter Cabri, Patrizia Minetti, Giovanni Piersanti, Giorgio Tarzia
  • Patent number: 9125903
    Abstract: The present invention relates to a composition useful for the treatment of lipid metabolism disorders, comprising one or more of the following active ingredients: (a) extract of rice fermented with Monascus purpureus, (b) at least one omega-3 fatty acid, (c) L-carnitine or a salt thereof; and one or more of the following active ingredients: (d) at least one policosanol or a natural extract containing policosanols; (e) resveratrol or a natural extract containing resveratrol; (f) Coenzyme Q10; and (g) at least one vitamin.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: September 8, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A.
    Inventors: Aleardo Koverech, Ashraf Virmani
  • Patent number: 9114120
    Abstract: It is described the use of L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the Leber optic neuropathy.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 25, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A.
    Inventors: Aleardo Koverech, Stefania D'Iddio, Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza
  • Patent number: 9084812
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 21, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
    Inventors: Franco Gaetani, Ashraf Virmani
  • Patent number: 9023861
    Abstract: The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: May 5, 2015
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Claudio Pisano, Loredana Vesci
  • Patent number: 8975248
    Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: March 10, 2015
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Sara Zaknoen, Margaret Ma Woo, Richard William Versace, Claudio Pisano, Loredana Vesci
  • Patent number: 8927533
    Abstract: The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: January 6, 2015
    Assignee: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Gianfranco Battistuzzi, Davide Vignola, Nicola Fanto', Claudio Pisano, Loredana Vesci
  • Patent number: 8883446
    Abstract: The present invention relates to an eukaryotic expression vector comprising a nucleotide sequence encoding for the human long pentraxin PTX3 protein under the control of an effective promoter and a nucleotide sequence encoding for a selectable marker, recombinant human cell able to provide expression of proteins encoded by the vector and method for the production of the human long pentraxin PTX3 protein.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: November 11, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Marica Sassano, Adelaide Esposito, Vincenzo Rivieccio, Giovanni Cassani
  • Patent number: 8853229
    Abstract: A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a synergistic effect and is useful in the treatment of disease forms due to insulin resistance and in cardiovascular diseases.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: October 7, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 8853233
    Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: October 7, 2014
    Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituto Nazionale per lo Studio e la Cura dei Tumori
    Inventors: Claudio Pisano, Loredana Vesci, Franco Zunino
  • Publication number: 20140294922
    Abstract: It is described the use of betamethasone as antibacterial agent.
    Type: Application
    Filed: December 1, 2011
    Publication date: October 2, 2014
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.
    Inventor: Aleardo Koverech
  • Publication number: 20140255512
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Franco GAETANI, Ashraf VIRMANI
  • Patent number: 8829021
    Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: September 9, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Pisano, Loredana Vesci, Paolo Carminati
  • Patent number: RE45968
    Abstract: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: SIGMA TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Olga Minenkova, Emiliano Pavoni